首页> 外文期刊>Brain research >Potential of GABA-ergic cell therapy for schizophrenia, neuropathic pain, and Alzheimer's and Parkinson's diseases
【24h】

Potential of GABA-ergic cell therapy for schizophrenia, neuropathic pain, and Alzheimer's and Parkinson's diseases

机译:GABA能细胞治疗精神分裂症,神经性疼痛以及阿尔茨海默氏症和帕金森氏病的潜力

获取原文
获取原文并翻译 | 示例

摘要

Several neurological and psychiatric disorders present hyperexcitability of neurons in specific regions of the brain or spinal cord, partly because of some loss and/or dysfunction of gamma amino butyric acid positive (GABA-ergic) inhibitory intemeurons. Strategies that enhance inhibitory neurotransmission in the affected brain regions may therefore ease several or most deficits linked to these disorders. This perception has incited a huge interest in testing the efficacy of GABA-ergic intemeuron cell grafting into regions of the brain or spinal cord exhibiting hyperexcitability, dearth of GABA-ergic intemeurons or impaired inhibitory neurotransmission, using preclinical models of neurological and psychiatric disorders. Intemeuron progenitors from the embryonic ventral telencephalon capable of differentiating into diverse subclasses of intemeurons have particularly received much consideration because of their ability for dispersion, migration and integration with the host neural circuitry after grafting. The goal of this review is to discuss the premise, scope and advancement of GABA-ergic cell therapy for easing neurological deficits in preclinical models of schizophrenia, chronic neuropathic pain, Alzheimer's disease and Parkinson's disease. As grafting studies in these prototypes have so far utilized either primary cells from the embryonic medial and lateral ganglionic eminences or neural progenitor cells expanded from these eminences as donor material, the proficiency of these cell types is highlighted. Moreover, future studies that are essential prior to considering the possible clinical application of these cells for the above neurological conditions are proposed. Particularly, the need for grafting studies utilizing medial ganglionic eminence-like progenitors generated from human pluripotent stem cells via directed differentiation approaches or somatic cells through direct reprogramming methods are emphasized. This article is part of a Special Issue entitled SI: PSC and the brain. (C) 2015 Published by Elsevier B.V.
机译:几种神经系统疾病和精神病性疾病在大脑或脊髓的特定区域表现出神经元过度兴奋,部分原因是γ氨基丁酸阳性(GABA刺激性)抑制性中间神经元的某些丧失和/或功能障碍。因此,在受影响的大脑区域增强抑制性神经传递的策略可能会缓解与这些疾病有关的一些或大多数缺陷。这种认识引起了极大的兴趣,需要使用神经病学和精神病学的临床前模型来测试将GABA诱导的内胚层细胞移植到表现出过度兴奋性,GABA诱导的内胚层缺乏或抑制性神经传递受损的大脑或脊髓区域的功效。来自胚胎腹侧端脑的能够分化为不同种类的间质的前体的祖细胞由于在移植后能够分散,迁移和与宿主神经回路整合而受到了特别的关注。这篇综述的目的是讨论减轻精神分裂症,慢性神经性疼痛,阿尔茨海默氏病和帕金森氏病临床前模型中神经功能缺损的GABA能细胞疗法的前提,范围和进展。到目前为止,由于这些原型的移植研究已经利用了来自胚胎内侧和外侧神经节隆起的原代细胞或从这些隆起扩展的神经祖细胞作为供体材料,因此突出了这些细胞类型的熟练程度。此外,提出了在考虑将这些细胞用于上述神经系统疾病的临床应用之前必不可少的未来研究。特别地,强调了需要利用通过定向分化方法从人多能干细胞或通过直接重编程方法从体细胞产生的内侧神经节突状样祖细胞进行移植研究的需求。本文是《 SI:PSC和大脑》一期特刊的一部分。 (C)2015由Elsevier B.V.发布

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号